Cybin Inc. at Morgan Stanley Global Healthcare Conference Transcript
Super. Well, good morning, everyone. Thank you for joining me today for this fireside chat with the CEO of Helus Pharma, Michael Halstead. Let me quickly read the Morgan Stanley research disclaimer. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures.
If you have any questions, please reach out to your Morgan Stanley sales representative. Michael, thank you very much for joining us this early in the morning. And before we get into the details, perhaps you can give us a bit of background on Helus Pharma and where the company is today.
Sure. And thank you, [Rebecca]. Thank you, everyone, for joining us today. Certainly excited to talk about Helus Pharma. I'm Michael Halstead, the new CEO of Helus.
I joined in early August. Helus Pharma is developing treatments for several mental health indications. We're
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
